Biotie's Stock Exchange Releases published in 2011
(Thomson Reuters ONE) -
BIOTIE THERAPIES CORP. STOCK EXCHANGE ANNOUNCEMENT 8 March 2012 at 9.05 a.m.
Biotie's Stock Exchange Releases published in 2011
The following list includes all Biotie Therapies Corp.'s Stock Exchange Releases
and Stock Exchange Announcements published in 2011.
Stock Exchange Releases, Stock Exchange Announcements and Press Releases
published by Biotie are available on the company's web site at
http://www.biotie.com/en/investors/releases
January
03.01.
Biotie Announces Positive Results from First Two Phase III Studies with
Nalmefene in Alcohol Dependence
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act
10.01.
Invitation to the Extraordinary General Meeting of Biotie Therapies Corp.
Biotie and Synosia to Combine to Create a Leading CNS Development Company
11.01.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act
12.01.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act
13.01.
Share capital increase registered with the trade register
19.01.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act
February
01.02.
Resolutions of the Extraordinary General Meeting of Biotie Therapies Corp. held
on 1 February 2011
A listing prospectus concerning listing of new shares in Biotie Therapies Corp.
has been published
02.02.
The acquisition of Synosia Therapeutics Holding AG completed
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act
03.02.
New Biotie Therapies Corp. shares and increase in share capital registered with
the trade register
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act
04.02.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act
07.02.
Amendment to Biotie Therapies Corp. Articles of Association registered
Organizational meeting of the Board of Directors of Biotie Therapies Corp.
Changes in Biotie's Financial Information in 2011
March
11.3.
Biotie raises EUR 27 million from institutional and strategic investors
15.3.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act
17.3.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act
18.3.
New Biotie shares and increase of share capital registered with the trade
register
22.3.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act
25.3.
Biotie Therapies Corp. financial statement release 1 January - 31 December 2010
Biotie's Annual Financial Report and Corporate Governance Statement 2010
published
Biotie's Stock Exchange Releases published in 2010
April
05.04.
Invitation to the Annual General Meeting of Biotie Therapies Corp.
07.04.
Biotie announces start of Phase 2b trial of SYN115 in Parkinson's disease
May
06.05.
Resolutions of the Annual General Meeting of Biotie Therapies Corp.
13.5.
Biotie Therapies Corp. interim report 1 January - 31 March 2011
24.5.
Biotie announces topline data from an exploratory phase 2a study with SYN118 in
Parkinson's disease
June
06.06.
Change in the number of votes relating to Biotie Therapies Corp.'s shares
15.6.
Biotie Announces Completion of Phase 3 Program with Nalmefene in Alcohol
Dependence; European Marketing Authorization Application (MAA) expected by the
end of 2011
July
05.07.
Change in the number of votes relating to Biotie Therapies Corp.'s shares
25.7.
Biotie Advances Clinical Program for SYN120 with Imaging Study at Johns Hopkins
Center of Excellence
26.7.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act regarding changes in number of votes
28.7.
Correction to Biotie Therapies Corp. interim report for January - March 2011
August
03.08.
Change in the number of votes relating to Biotie Therapies Corp.'s shares
05.08.
Biotie Therapies Corp. Interim report 1 January - 30 June 2011
September
01.09.
New interim CFO in Biotie
02.09.
Change in the number of votes relating to Biotie Therapies Corp.'s shares
27.9.
Biotie to Acquire Newron Creating a Leading European Biopharmaceutical Company
Focused on Central Nervous System Drug Development
October
05.10.
Notice to Biotie shareholders on registration of merger plan and documents
available for review
21.10.
Biotie informed that Merck Serono is returning full global rights for safinamide
to Newron
28.10.
Biotie Terminates the Agreement to Acquire Newron
November
04.11.
Biotie's Financial Information in 2012
Biotie Updates Outlook - Non-cash Impairment Charge for SYN118
Biotie Therapies Corp. Interim report 1 January - 30 September 2011
23.11.
Biotie provides UCB partnership update on SYN118
28.11.
Biotie's loan obligations to Tekes reduced by EUR 2.2 million
December
02.12.
Change in the number of votes relating to Biotie Therapies Corp.'s shares
07.12.
The Board of Directors of Biotie Therapies Corp. Decided on Incentive Plans for
Employees
13.12.
US National Institute on Drug Abuse (NIDA) to Conduct Clinical Study on Biotie's
Nepicastat in Cocaine Dependence
21.12.
Biotie's partner Lundbeck submits European Marketing Authorization Application
for Selincro(TM) (nalmefene)
Turku, March 8, 2012
Biotie Therapies Corp.
Timo Veromaa
President and CEO
For further information, please contact:
Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail:virve.nurmi(at)biotie.com
Distribution:
NASDAQ OMX Helsinki Ltd
Main Media
About Biotie
Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease,
Alzheimer's disease and other cognitive disorders, alcohol and drug dependence
(addiction) and post traumatic stress disorder), and inflammatory and fibrotic
liver disease.
The company has a strong and balanced development portfolio with several
innovative small molecule and biological drug candidates at different stages of
clinical development. Biotie's products address diseases with high unmet medical
need and significant market potential.
Partnerships with top-tier pharmaceutical partners are in place for several
programs as well as a strategic collaboration with UCB Pharma S.A. The Marketing
Authorization Application for Biotie's most advanced product, Selincro(TM)
(nalmefene) for alcohol dependence was filed in the EU by our partner H.
Lundbeck A/S and was accepted for review by the European Medicines Agency in
December 2011.
Biotie shares are listed on NASDAQ OMX Helsinki Ltd.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biotie Therapies Oyj via Thomson Reuters ONE
[HUG#1592333]
Unternehmensinformation / Kurzprofil:
Datum: 08.03.2012 - 08:05 Uhr
Sprache: Deutsch
News-ID 123024
Anzahl Zeichen: 8764
contact information:
Town:
Turku
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 159 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biotie's Stock Exchange Releases published in 2011"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotie Therapies Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
